More data sought on Arcoxia

As expected, the FDA has told Merck that it will need to provide more safety data on Arcoxia before it can be approved as a successor to Vioxx, its Cox-2 inhibitor pulled after being linked to scores of heart attacks and strokes. Merck said this morning that it will continue with two late-stage trials of Arcoxia, including one two-year trial. Merck says that it will provide new data from the Phase III trials in 2006.

- read this article from the AP for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.